Quantum BioPharma Stock Surges on MS Imaging Breakthrough

Benzinga reported Thursday that Quantum BioPharma MS imaging data has sent shares of the small-cap biotech sharply higher, with the stock closing up more than 8% on Wednesday and adding nearly 5% in pre-market trade the following morning.

Enrollment Milestone Sparks Investor Interest

NASDAQ-listed Quantum BioPharma Ltd. (QNTM) disclosed that patient enrollment in its ongoing multiple sclerosis collaboration has cleared the halfway mark. The company simultaneously released early data from a novel PET imaging method designed to measure myelin loss directly in the brain. The technique uses a radioactive tracer called [¹⁸F]3F4AP to visualize active MS lesions. Researchers said the preliminary imaging quality was strong, raising hopes for a more precise way to track disease progression over time.

Also Read: What Is a Biotech Catalyst and Why Does It Move Stocks?

Why Measuring Myelin Loss Matters

Background on the MS Research Gap

Multiple sclerosis damages the myelin sheath that insulates nerve fibers, and measuring that damage precisely has long challenged clinicians. Existing imaging tools offer only indirect signals. Dr. Pedro Brugarolas of Massachusetts General Hospital, a collaborator on the study, said the PET approach could give researchers a more direct window into myelin damage. That would address a long-standing gap in the field. Quantum’s experimental therapy, Lucid-MS, is designed to protect myelin by blocking biological pathways linked to nerve deterioration. The company argues the imaging platform could serve as a tool to test whether treatments like Lucid-MS genuinely slow or reverse damage.

Also Read: Multiple Sclerosis Research Explained: The Role of Myelin Imaging

Executive Confidence and Fundraising Questions

Vice-President of Scientific and Clinical Affairs Dr. Andrzej Chruscinski said the team was encouraged by the strength of the early data and described the imaging technique as potentially transformative for assessing demyelination in clinical settings. Separately, Kevin Malone, President and CEO of Malone Wealth, posted on X that Quantum may have left significant capital on the table by raising funds earlier in the year. He argued that aligning share issuance with market cycles and technical patterns could have produced substantially higher proceeds. The company has not responded publicly to that assessment.

Price Action and Trend Signals

Quantum BioPharma’s momentum score jumped from roughly 17 to 84 on a week-over-week basis, according to Benzinga’s stock ranking system. Short- and medium-term price trends have turned positive, though the longer-term trend remains negative. The stock closed at $7.64 on Wednesday before extending gains in pre-market trading Thursday morning.

Read Next: Small-Cap Biotech Stocks to Watch This Earnings Season